NeOnc Technologies Holdings, Inc. Common Stock (NTHI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
NeOnc Technologies Holdings, Inc. Common Stock stock (NTHI) is currently trading at $7.53. NeOnc Technologies Holdings, Inc. Common Stock PS ratio (Price-to-Sales) is 3200.97. WallStSmart rates NTHI as Sell.
- NTHI PE ratio analysis and historical PE chart
- NTHI PS ratio (Price-to-Sales) history and trend
- NTHI intrinsic value — DCF, Graham Number, EPV models
- NTHI stock price prediction 2025 2026 2027 2028 2029 2030
- NTHI fair value vs current price
- NTHI insider transactions and insider buying
- Is NTHI undervalued or overvalued?
- NeOnc Technologies Holdings, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- NTHI Piotroski F-Score and Altman Z-Score
- NTHI analyst price target and Smart Rating
NeOnc Technologies Holdings, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
NeOnc Technologies Holdings, Inc. Common Stock (NTHI) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
NeOnc Technologies Holdings, Inc. Common Stock (NTHI) Key Strengths (0)
NeOnc Technologies Holdings, Inc. Common Stock (NTHI) Areas to Watch (5)
Losing money on operations
Revenue declining -7.00%, a shrinking business
Very expensive at 3201.0x annual revenue
Very low institutional interest at 9.39%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
NeOnc Technologies Holdings, Inc. Common Stock (NTHI) Detailed Analysis Report
Overall Assessment
This company scores 6/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 0 register as strengths (avg 0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (3200.97) suggest expensive pricing. Growth concerns include Revenue Growth at -7.00%, which may limit upside. Profitability pressure is visible in Operating Margin at -77706.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -77706.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -7.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NTHI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NTHI's Price-to-Sales ratio of 3200.97x sits near its historical average of 3616.97x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 22% below its historical high of 4083.71x set in Mar 2026, and 0% above its historical low of 3200.97x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~4083.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for NeOnc Technologies Holdings, Inc. Common Stock (NTHI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
NeOnc Technologies Holdings, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. Revenue reached 59,990 with 7% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of -0.03 indicates a conservative balance sheet with 2M in cash.
Spending 1192% of revenue (715,038) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 7% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact NeOnc Technologies Holdings, Inc. Common Stock.
Bottom Line
NeOnc Technologies Holdings, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About NeOnc Technologies Holdings, Inc. Common Stock(NTHI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
NeOnc Technologies Holdings, Inc. is a biotechnology company focused on the development and commercialization of cutting-edge cancer therapies, primarily through immunotherapy and molecular medicine. With a robust pipeline of innovative product candidates aimed at addressing significant unmet needs in oncology, NeOnc is well-positioned to transform treatment paradigms and improve patient outcomes. The company's strategic partnerships within the biopharmaceutical industry enhance its ability to advance its therapeutic innovations, making it a compelling investment opportunity in the fast-growing cancer therapeutics space.